Neeman & Industry News
DCGI to implement e-Gov in its working The Drugs Controller General of India (DCGI) to have a single window facility for drug approval soon...
India’s nutrition boom produces contract research boon As the need for scientific support for potential health claims for healthy foods increases, India is leveraging its pharmaceutical expertise to take a bite of the functional foods pie. ...
New Indian Regulatory Guidance by Central Drugs Standard Control Organization Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy - Central Drugs Standard Control Organization...
Indian Clinical Data Management market is expected to ramp up to $150 million MNCs are more than willing to outsource their needs to India because of it\'s technological innovation, creditable quality, operational flexibility, cost effectiveness, time-to-market and competitive advantage according to Koteshwar Govind, Deputy Manager,...
India: Attractive Market for Biopharmaceutical Companies Looking to Accelerate Their Clinical Trials The Clinical Research Market in India is growing at a very rapid rate according to anyone’s statistics…It is exploding according to all the hype. ...
This sitemap has been provided to help you access any page on this website at just a click of the button. Happy browsing!

Home
About Us
  The Parent Company Max
  Max Neeman International
    Vision & Mission
    Milestones
    Core Values
    Management Team
    Our Presence
    Why India
    Certifications & Accreditation
Services
  Monitoring Services
    Monitoring
    Regulatory Service
    Medical Monitoring
    Medical And Other Scientific Services
  Data Management & Medical Writing
  Project Management
  Central Ware House Services
  Regulatory Service
    Indian Regulatory
  Site Management
    Site Feasibility & Site Selection
    Ethics Committee Submission & Approval
    Regulatory Services
    Drug Warehousing/ Drug Supply Management
    Site Coordination
  Pharmacovigilance
  Clinical Auditing and Training
    Clinical Audit Services
    Training
  Central Lab
    Overview
    Safety Testing
    Service Offerings
Max Neeman Differentiators
  Overview
  Nutraceuticals
  Biosimilars
  Cosmetics
Testimonials
Max Neeman SOPs
  DATA MANAGEMENT
  MONITORING DEPARTMENT
  SITE MANAGEMENT
  IT SECURITY
  MSW
  QUALITY ASSURANCE
  PHARMACY
  ADMINISTRATIVE
  REGULATORY
  BUSINESS DEVELOPMENT
  HR SOPs
  FINANCE SOPs
  LABORATORY SERVICES
Therapeutic Area Expertise
  Overview
  Dermatology
  Oncology
    Chemotherapy Induced Nausea & Vomiting
    Colorectal Carcinoma
    Esophageal Cancer
    Head and neck Cancer
    Lung Carcinoma
    Oral Cancer
    Ovarian Cancer
    Prostate Cancer
    Cervical Cancer
  Neurology and Neuro-Surgery
    Alzheimer's Disease
    Multiple Sclerosis
    Parkinson's Disease
  Endocrinology & Metabolic disorders
    Diabetes
  Cardiology
    Acute Coronary Syndrome
    Acute Myocardial Infarction
    Angina pectoris
    Atherosclerosis
    Cardiac Arrhythmia
    Hypertension
  HIV/AIDS
  Pulmonology
    Bronchial Asthma
    Chronic Obstructive Pulmonary Disease
  Psychiatry
  Gastroenterology
  Ophthalmology
Data Management
  Data Management Services
Careers
  Culture Of Max Neeman
  Testimonials
  Submit Your Resume
  Current Openings
Contact Us
Links
FAQs
Site Map
Max Neeman Mails
Disclaimer
Upcoming Conferences
Monitoring Unit Knowledge Pool
Knowledge Management
  Articles
  Friday Training Presentations
  Max Medical Journals
  Study Resources
  General Presentations
Devices
  Device Studies
  Case Studies
  Device Trial Regulation
Contact For Feasibility
Discussion Forum
Neeman News
Industry News